Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572900 | 1.00 | GCK (0.37) | GCKPIN1VCAM1HCAR3LMNA | |
| SCHEMBL22804656 | 1.00 | GCK (0.37) | GCKPIN1VCAM1HCAR3LMNA | |
| SCHEMBL15283821 | 0.83 | PDK1 (0.45) | PIN1LMNANPC1 | |
| SCHEMBL29811740 | 0.78 | PIN1 (0.50) | PIN1LMNANPC1 | |
| SCHEMBL1100650 | 0.78 | PIN1 (0.50) | PIN1LMNANPC1 | |
| SCHEMBL25009352 | 0.77 | MCHR1 (0.37) | GCKABL1 | |
| SCHEMBL25001114 | 0.77 | MCHR1 (0.37) | GCKABL1 | |
| SCHEMBL2657961 | 0.76 | S1PR4 (0.41) | GCKLMNAS1PR4NPC1 | |
| SCHEMBL25009529 | 0.76 | MCHR1 (0.42) | GCKABL1 | |
| SCHEMBL25000952 | 0.76 | MCHR1 (0.42) | GCKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479820-B2 | Pyridin-3-yl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| CN-114026082-B | Pyridin-3-yl derivatives | 爱杜西亚药品有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20220251068-A1 | PYRIDIN-3-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-11 | — | — | US | disclosed |
| EP-3986884-A1 | PYRIDIN-3-YL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114026082-A | Pyridin-3-yl derivatives | 爱杜西亚药品有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2020254408-A1 | PYRIDIN-3-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251068-A1 | PYRIDIN-3-YL DERIVATIVES | LPAR1, LPAR3, LPAR2 | GCK 3789/4885PIN1 4478/4885VCAM1 1288/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | GCK 2850/4885PIN1 3062/4885VCAM1 712/4885 |
| US-12479820-B2 | Pyridin-3-yl derivatives | LPAR1, LPAR3, LPAR2 | GCK 3789/4885PIN1 4478/4885VCAM1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.